Verquvo (vericiguat) / Bayer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 2 Diseases   27 Trials   27 Trials   1089 News 


«12345678910111213...1516»
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Review, Journal:  A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure. (Pubmed Central) -  Aug 2, 2023   
    Furthermore, larger studies are required to investigate any potential effect of vericiguat in HFpEF patients. Despite the limitations, vericiguat can be recommended for patients with HFrEF, where standard-of-care is insufficient, and the disease worsens.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Preclinical, Journal:  Vericiguat preserved cardiac function and mitochondrial quality in a rat model of mitral regurgitation. (Pubmed Central) -  Jul 24, 2023   
    Despite the limitations, vericiguat can be recommended for patients with HFrEF, where standard-of-care is insufficient, and the disease worsens. Vericiguat demonstrated cardioprotective effects on cardiac function, BP, and fibrosis by preserving mitochondrial quality in rats with HF due to MR.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD), Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, omecamtiv mecarbil (AMG 423) / Amgen, Servier
    PN216. The Ejection Fraction is Low, and Stress Levels Are High: Newer Therapies for HFrEF and Implications for the Anesthesiologist (South: 310/311/312) -  Jul 20, 2023 - Abstract #ASA2023ASA_2141;    
    Session Learning Objective 2: List the salient indications for and implications of newer implantable devices for the management of HFrEF. Session Learning Objective 3: Apply the the latest updates from national and international consensus guidelines by describing contrasting recommendations concerning the perioperative management of heart failure patients.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Enrollment open, Trial completion date, Trial primary completion date:  A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction (clinicaltrials.gov) -  Jul 20, 2023   
    P2,  N=50, Recruiting, 
    Session Learning Objective 3: Apply the the latest updates from national and international consensus guidelines by describing contrasting recommendations concerning the perioperative management of heart failure patients. Not yet recruiting --> Recruiting | Trial completion date: Apr 2028 --> Jul 2028 | Trial primary completion date: Apr 2028 --> Jul 2028
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Clinical data, Journal:  Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial. (Pubmed Central) -  Jul 7, 2023   
    P3
    Patients in VICTORIA were well treated with heart failure with reduced ejection fraction medications. The efficacy of vericiguat was consistent across background therapy with very high adherence to guidelines accounting for patient-level indications, contraindications, and tolerance.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Response to Letter of Liansheng Wang on Vericiguat in HFrEF. (Pubmed Central) -  Jul 5, 2023   
    The efficacy of vericiguat was consistent across background therapy with very high adherence to guidelines accounting for patient-level indications, contraindications, and tolerance. No abstract available
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Preclinical, Journal:  The treatment with sGC stimulator improves survival of hypertensive rats in response to volume-overload induced by aorto-caval fistula. (Pubmed Central) -  Jun 20, 2023   
    Using a practical approach, this review analyzes the importance of worsening HF events, with special emphasis on Spanish data. In the current study, we aimed to investigate the effectiveness of sGC stimulator (BAY41-8543) with the same mode of action as vericiguat, for the treatment of heart failure (HF) with cardio-renal syndrome...Moreover, sGC stimulator caused a decrease in SBP, but this effect was only temporary (day 0: 117?
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat. (Pubmed Central) -  Jun 19, 2023   
    Significance Statement There was no evidence of increased proarrhythmic risk from in vitro and in vivo nonclinical studies with vericiguat or M-1. The integrated risk assessment of these nonclinical data combined with existing clinical data demonstrate administration of vericiguat 10 mg once daily in patients with heart failure with reduced ejection fraction is not associated with a proarrhythmic risk.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Biomarker, Review, Journal:  The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction. (Pubmed Central) -  Jun 10, 2023   
    Furthermore, we provide a description of conditions other than congestion with increased congestion biomarkers, in order to aid in reaching a differential diagnosis. To conclude, the review focuses on how congestion biomarkers may be affected by new HF drugs (gliflozins, vericiguat, etc.) approved for HFrEF.
  • ||||||||||  Camzyos (mavacamten) / BMS
    PK/PD data, Preclinical, Journal:  Effects of CYP2C19 inhibitors on mavacamten pharmacokinetics in rats based on UPLC-MS/MS. (Pubmed Central) -  Jun 5, 2023   
    To conclude, the review focuses on how congestion biomarkers may be affected by new HF drugs (gliflozins, vericiguat, etc.) approved for HFrEF. The results showed that CYP2C19 inhibitors could significantly improve the bioavailability of mavacamten in rats, which indicated that we should pay more attention to the patient's condition to prevent the occurrence of side effects when used mavacamten in combination with CYP2C19 inhibitors.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Trial initiation date:  Impact of Vericiguat on Hemodynamics of Heart Failure (clinicaltrials.gov) -  May 18, 2023   
    P4,  N=30, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Apr 2023 --> Jul 2023
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Effects of vericiguat on redox signaling in cardiomyocyte (Station 3) -  May 13, 2023 - Abstract #ESC2023ESC_4821;    
    Our results indicated that vericiguat could suppress the oxidative stress induced by angiotensin II and following activation of ERK 1/2 signaling. Suppressing the oxidative stress could lead to further activation of NO-sGC-cGMP pathway not only the stimulation by vericiguat and favorable cardio-protective cycle is expected.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    SGLT2 inhibitors and vericiguat in real-world patients admitted for worsening heart failure (Station 4) -  May 13, 2023 - Abstract #ESC2023ESC_4601;    
    At the moment, vericiguat can be used only in patients with EF < 45% and this is the most limiting factor, whereas SGLT2i can be used regardless of EF. These data show that their applicability is high in patients with WHF and that the characteristics of trials populations reflect a real-world population.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Effect of vericiguat on cardiovascular outcomes in patients with heart failure with and without diabetes: Insights from the VICTORIA trial (Station 3) -  May 13, 2023 - Abstract #ESC2023ESC_4332;    
    These data show that their applicability is high in patients with WHF and that the characteristics of trials populations reflect a real-world population. Notwithstanding the increased incidence of cardiovascular death and HHF conferred by T2D, in this post-hoc analysis of VICTORIA, vericiguat compared with placebo significantly reduced the risk of cardiovascular death or HHF in patients with worsening HFrEF regardless of T2D status.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Candidacy and predicted efficacy of vericiguat in contemporary heart failure outpatient clinics (Station 3) -  May 13, 2023 - Abstract #ESC2023ESC_3714;    
    Based on NT-proBNP levels, the proportion likely to experience net and strong beneficial effects from Vericiguat were 15.6% and 12.6% respectively. Considering Vericiguat has advantages over the traditional barriers (hypotension, renal function) of conventional HFrEF pharmacotherapy agents, our findings provide insight into the potential real-world use of Vericiguat within contemporary HF OPD clinics.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Diuretic use and outcomes in patients with HFrEF: Insights from the VICTORIA trial (Science Box 2) -  May 13, 2023 - Abstract #ESC2023ESC_2789;    
    The amount of loop diuretic TDD at randomization was associated with a higher risk phenotype commensurate with worse outcomes. However, the efficacy of vericiguat was preserved across this range of different loop diuretic doses used by patients with recent WHF in VICTORIA.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Clinical, Journal:  Prospects for use of Vericiguat in HFrEF: Implications of VICTORIA Trial Results. Advisory Board Summary (Pubmed Central) -  May 11, 2023   
    The objective of the VICTORIA study was evaluation of the efficacy and safety of supplementing a standard therapy with vericiguat at a target dose of 10 mg twice a day as compared to placebo for prevention of cardiovascular death and hospitalization for heart failure (HF) in patients with clinical manifestations of chronic HF and left ventricular ejection fraction <45% who have recently had an episode of decompensated HF. The aim of the meeting was interpretation of the VICTORIA study results on efficacy and safety of vericiguat for a potential use in a Russian population of patients after a recent episode of decompensated chronic HF with reduced ejection fraction.
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Chronic heart failure: the role of di vericiguat. (Pubmed Central) -  May 1, 2023   
    In these patients, vericiguat reduced the primary outcome of death from cardiovascular causes or first hospitalization for heart failure in comparison with placebo. By reducing hospital admissions in a population at a very high risk of re-hospitalization, vericiguat might have a positive impact on healthcare costs for the management of HFrEF.